Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
[6] Phase III ACHIEVE-1 trial [edit] In April 2025, results from a phase III clinical trial involving 559 people with type 2 diabetes who took an oral orforglipron pill or a placebo daily for 40 weeks showed that orforglipron produced a reduction of hemoglobin A1C level by 1.3 to 1.6 percentage points from a starting level of 8%
This isn't a reason to avoid GLP-1 therapy the benefits are well established but it is a compelling reason to be proactive about your B12 status
Nonetheless, the quality, precision, and consistency across studies is very varied and the overall volume of studies on this topic is also very low, revealing that these results have low certainty
Prescription benefits vary widely
Early follow-up within a few weeks of starting is common, then regular reviews every few months to check progress and side effects
,
US$ 26.31
US$ 26.59
US$ 29.89
US$ 27.88
US$ 25.44
US$ 26.27
US$ 24.53
US$ 22.61
US$ 20.86
US$ 29.08
